Company News

Ayurcann Holdings Corp. a Canadian cannabis extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to announce that it has won Extraction Facility of the Year and Toll Processing Facility of the Year at the 2021 GrowUp Awards Gala in Niagara Falls, Ontario, Canada. Ayurcann is a growing extraction company continuously ...

Ayurcann Holdings Corp. ( CSE: AYUR OTCQB: CDCLF FSE:3ZQ0 ) (the "Company" or "Ayurcann") a Canadian cannabis extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to announce that it has won Extraction Facility of the Year and Toll Processing Facility of the Year at the 2021 GrowUp Awards Gala in Niagara Falls, Ontario, Canada.

Ayurcann is a growing extraction company continuously incorporating new and strategic business approaches to maintain their industry leading services. With an annual extraction capacity of up to 300,000 kg, Ayurcann can supply bulk or formulated THC and CBD products to industry leaders while also offering a competitive advantage through their white labelling services.

Roman Buzaker, President of Ayurcann writes "None of this could have happened without you. Our hard work and dedication brought results noticed by the industry. We are a fast and growing team, who did what many didn't believe is possible - become a new player that leads the industry forward. A lot of work is still ahead of us and in no way means we can relax, but this is a significant milestone that shows what real teamwork looks like. This confirms that we are the leading Cannabis 2.0 producer in Canada!".

Igal Sudman, CEO of Ayurcann states "We are confident in our ability to meet the demands of our existing and future partners. What separates us from our competitors is our team. Each employee is professional, confident in their abilities, and truly cares for the success and growth of the company.".

For further information, please contact:

Igal Sudman, Chairman and CEO
Ayurcann Holdings Corp.
Tel: 905-492-3322
Email: info@Ayurcann.com

Investor Relations:
Ryan Bilodeau
Tel: 416-910-1440
Email: ir@ayurcann.com

About Ayurcann Holdings Corp.:

Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada. Ayurcann is striving to become a partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including extraction, formulation, product development and custom manufacturing.

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward- looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements, including but not limited to statements relating to the Company's expansion plans and future production capacity. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties, and other factors.

Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include, but are not limited to, failure to obtain regulatory approval, ability to increase production at the Company's facilities, the continued availability of capital and financing, and general economic, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, Further, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. Public health crises, including the ongoing novel coronavirus (COVID-19) pandemic, could have significant economic and geopolitical impacts that may adversely affect the Company's business, financial condition and/or results of operations.  The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.

Attachment


News Provided by GlobeNewswire via QuoteMedia

Ayurcann

Ayurcann

Overview

Keep reading... Show less
business meeting evaluating financial results

Cannabis Weekly Round-Up: Organigram Results Improve, Ascend Ready for Lawsuit

A Canadian cannabis producer beat estimates in its latest financial results, and experts believe it may be showing signs of achieving profitability.

Also this week, Ascend Wellness Holdings (AWH) (CSE:AAWH.U,OTCQX:AAWH) revealed it will be taking its dispute with MedMen Enterprises (CSE:MMEN,OTCQX:MMNFF) to court.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading... Show less
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

The trial evaluates Numinus' first trademarked product and patent-pending production process

 Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has formally submitted the clinical trial application ("CTA") to Health Canada for its Phase 1 study, HOPE, on a naturally derived Psilocybe extract formulation, NBIO-01. This milestone further progresses and solidifies Numinus' long-standing work on developing safe and effective psychedelic products out of its Health Canada-licensed research facility, Numinus Bioscience.

Keep reading... Show less
Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.

Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.

Expansion and fortification of relationship since 2020 with established pharmaceutical company in Chile

Supply of Avicanna's active pharmaceutical ingredients for existing commercial and pipeline of pharmaceutical products in South America

Keep reading... Show less
Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders

Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders

Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today that its annual general meeting of shareholders (the "AGM"), which was originally scheduled to be held on Friday, January 21, 2022 has been cancelled and rescheduled to be held on February 28 2022. The Company's Board of Directors determined that it would be in the best interests of the Company to reschedule the AGM for a variety of reasons, including a change to at least one resolution.

Further details on the AGM will be contained in a new Notice of Meeting and Management Information Circular that will be mailed to shareholders of the Company and filed on SEDAR.

Keep reading... Show less

IIROC Trade Resumption - CL

Trading resumes in:

Company: Cresco Labs Inc.

Keep reading... Show less

IIROC Trading Halt - CL

The following issues have been halted by IIROC:

Company: Cresco Labs Inc.

Keep reading... Show less

Latest Press Releases

Related News

×